Congreso EAACI 2024: Innovación y Avances en el Tratamiento de Alergias
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Durante el congreso se presentarán más de 150 sesiones científicas centradas en los avances en ciencia medioambiental, alergias alimentarias, innovaciones en inmunoterapia o alergias pediátricas,...
Kongres EAACI 2024: Inovasi dan Kemajuan dalam Rawatan Alahan
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Lebih 150 sesi saintifik akan dibentangkan semasa kongres itu, yang antara lainnya memfokuskan kepada kemajuan dalam sains alam sekitar, alahan makanan, inovasi dalam imunoterapi dan alahan...
2024년도 EAACI 학술대회: 알레르기 치료의 혁신과 발전
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
학술대회 일환으로 환경 과학, 식품 알레르기, 면역 치료 혁신, 소아 알레르기 등의 주제에 초점 맞춘 150개 이상의 과학 세션 열릴 예정최대 규모의 알레르기 및 면역학 학술대회에서 다뤄질 정밀 의학, AI, 면역 치료, 면역 조절제5월 31일부터 6월 3일까지 스페인 발렌시아에서 개최 스페인 발렌시아, April 30, 2024 (GLOBE...
Medigene AG reports Financial Results and Business Update for Q1 2024
April 26, 2024 03:00 ET
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
April 25, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Medigene to Present at Upcoming Scientific Conferences
April 17, 2024 06:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
April 08, 2024 02:00 ET
|
Medigene AG
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Secures European Patent for its iM-TCR Technology
April 04, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 02:30 ET
|
Medigene AG
Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program...